VYNE Therapeutics just posted Q1 results after market close on May 15 — and the print is the week's defining tension. EPS came in at –$0.08, beating the –$0.18 estimate by ten cents. Revenue of $86,000 missed the $200,000 consensus by more than half. The gap between the beat and the miss captures where the company stands: it's burning less than feared, but generating almost nothing.
The lending market tells a story of rising but not extreme short pressure. Short interest jumped nearly 5× over the past week, now sitting at roughly 0.14% of the free float — a very low absolute level, but the pace of movement is hard to ignore. At the same time, the borrow pool is almost fully tapped: availability has tightened to a point where fewer than one share remains for every twenty already lent out, with the borrow pool at 95% used as of May 14 — within sight of the 100% ceiling it hit as recently as May 8. Cost to borrow has roughly doubled over the week to 0.66% but remains low in absolute terms, meaning short pressure is present though not yet costly to maintain.
The Street is quiet after a damaging downgrade. HC Wainwright downgraded to Neutral from Buy last July, ending a long streak of maintained Buy ratings, and no fresh coverage has appeared since. Two analysts cover the stock, both on Hold. The price targets on record — ranging from $4.50 to $8.00 — are stale relative to today's $0.67 price, and the gap is too wide to reconcile cleanly; those targets likely reflect a pre-bear-case pipeline view that no longer holds. The company's own 10-Q landed Thursday alongside the earnings, and Nantahala Capital Management filed a 13G the same day, signalling its position remains a formal stake. Factor scores are modest — a utilization rank in the bottom 3% of the universe captures just how tightly lent-out this small float is, while the short score of 45.2 sits near the midpoint, consistent with moderate but not extreme bearish conviction.
Insider activity across Q4 2025 and Q1 2026 shows a consistent pattern of small sales at the executive level — CEO, CFO, Chief Legal Officer, and Chief Scientific Officer all sold in both December and March. None of the transactions was large in dollar terms (the March cluster totalled roughly $15,000 across all four), and the prices were below current levels, so these reads low-significance. The more notable ownership event is Lynx1 Capital Management, which added its full 1.6 million share position in the quarter ended March 31, becoming the largest single institutional holder at roughly 4.9% of shares. That fresh entry stands against the clinical setback backdrop — VYNE's bear case centres on the Phase 2b vitiligo trial failure, the missed primary endpoint, and the termination that followed.
What to watch next is whether the Q1 10-Q filing and the Nantahala 13G — both filed the same evening as earnings — contain any forward-looking commentary on pipeline pivots or cash runway, given the company held approximately $40 million in cash at last count. Revenue of $86,000 for the quarter makes cash burn, not pipeline success, the single variable that matters most right now.
See the live data behind this article on ORTEX.
Open VYNE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
